Is PT-141 (Bremelanotide) Legal in Virginia?

HealthRX.com

Vyleesi is legal in Virginia with a prescription

Print or save as PDF

Key numbers

  • 1.75 mgVyleesi single-dose autoinjector strength for premenopausal women with acquired HSDDSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 40.0%Share of Vyleesi users with nausea in pooled phase 3 trials (placebo: 1.3%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 8 dosesMaximum Vyleesi doses per month the label says is not recommended to exceedSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 18%Share of Vyleesi users who stopped due to adverse reactions in phase 3 (placebo: 2%)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Bremelanotide

  • Drug name / Bremelanotide, approved as Vyleesi; 'PT-141' is the common research name
  • Approval / NDA 210557, June 21, 2019 [1][2]
  • Approved use / Premenopausal women with acquired, generalized HSDD [1]
  • Dose and route / 1.75 mg subcutaneous autoinjector, as needed, at least 45 minutes before activity (per the label) [1]
  • Regulatory status / Prescription-only; no boxed warning and no REMS [1][2]
  • Compounded PT-141 / Not FDA-approved; not reviewed for safety, effectiveness or quality [4]
  • Virginia rules / Drug Control Act: prescriptions, compounding, pharmacy permits [3]

What federal approval does and does not cover

FDA approved bremelanotide under NDA 210557 on June 21, 2019 [2]. It is sold as Vyleesi, a prefilled autoinjector. The label gives the dose as 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The label says not to give more than one dose within 24 hours and that more than 8 doses per month is not recommended [1].

The approval is narrow. Vyleesi is indicated for premenopausal women with acquired, generalized HSDD: low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1]. Vyleesi carries no boxed warning and no risk evaluation and mitigation strategy [1][2].

Compounded and research-use PT-141 is a different product

Products sold as PT-141 by peptide vendors and compounding pharmacies are not Vyleesi, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed [4]. Bremelanotide does not appear on FDA's list of bulk substances that may present significant safety risks, in the version of that page dated 04/22/2026 [5], and it is not one of the six peptides addressed by HHS's October 2026 draft enforcement-discretion policy [6]. Absence from those lists is not an FDA approval.

What Virginia's Drug Control Act covers

Virginia regulates drugs through Chapter 34 of Title 54.1, the Drug Control Act [3]. Its sections include requirements for prescriptions (§ 54.1-3408.01), a pharmacist's authority to compound under certain conditions (§ 54.1-3410.2), a section titled "Prohibition on refusing to fill prescription from telemedicine provider" (§ 54.1-3420.3), a permit to conduct a pharmacy (§ 54.1-3434) and a permit to act as an outsourcing facility (§ 54.1-3434.05) [3]. These are the general state provisions for prescriptions and pharmacies.

Key label safety points

The label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease [1]. Each dose transiently raises blood pressure and lowers heart rate, with maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours after the dose and returning to baseline usually within 12 hours [1]. In the pooled phase 3 trials, nausea occurred in 40.0% of Vyleesi users versus 1.3% on placebo, and flushing in 20.3% versus 0.3%; 18% of Vyleesi users discontinued because of adverse reactions versus 2% on placebo [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, how long before anticipated sexual activity does the Vyleesi label say to give a dose?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Questions worth asking

Choose the questions you want to keep

Is PT-141 (Bremelanotide) legal in Virginia?
Bremelanotide is legal in Virginia as an FDA-approved prescription drug, sold as Vyleesi at 1.75 mg per autoinjector dose [1][2]. Compounded or research-use PT-141 is a different product that FDA has not approved [4].
Do I need a prescription for PT-141 in Virginia?
The approved product does. Vyleesi is prescription-only and self-injected at 1.75 mg subcutaneously as needed. The label says not to give more than one dose within 24 hours and that more than 8 doses per month is not recommended [1].
Is there an over-the-counter version of bremelanotide?
No. The FDA-approved bremelanotide product, Vyleesi, is prescription-only [1], and the PT-141 sold by peptide vendors is not that product [4].
Is compounded PT-141 legal in Virginia?
Virginia allows pharmacists to compound drugs under certain conditions [3], but that does not establish that every compounded PT-141 product is lawful. Compounded PT-141 is not FDA-approved or reviewed by FDA before marketing [4].
Can a Virginia pharmacy fill a telehealth prescription for Vyleesi?
The Drug Control Act includes a section titled Prohibition on refusing to fill prescription from telemedicine provider (§ 54.1-3420.3) [3].
Does the Vyleesi label cover men?
No. The label says Vyleesi is not indicated for HSDD in men or in postmenopausal women, and is not indicated to enhance sexual performance [1].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is PT-141 legal?

Yes, with a prescription, for the FDA-approved product Vyleesi, which FDA approved on June 21, 2019 for premenopausal women with acquired, generalized HSDD. Compounded or research-use PT-141 is not Vyleesi and is not FDA-approved or reviewed by FDA for safety, effectiveness or quality.

Does PT-141 work for everyone?

Not established. Vyleesi is approved only for premenopausal women with acquired, generalized HSDD. The label says it is not indicated for HSDD in postmenopausal women or in men, or to enhance sexual performance, and it is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

When is the best time to inject PT-141?

The label says to inject 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. Do not give more than one dose within 24 hours, and more than 8 doses per month is not recommended.

Show all 6 referencesHide references
PT-141 legal Virginia: evidence summary chart
Image: HealthRX.com. Full PT-141 legal Virginia guide and sources at healthrx.com/peptide-legal-pt-141.